Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in small molecule therapeutics, announced updated positive results from their Phase 1 ENABLE clinical trial of ELVN-001 for chronic myeloid leukemia $(CML.UK)$. The data was presented at the European Hematology Association (EHA) 2025 Congress, taking place from June 12-15 in Milan, Italy, and virtually. The trial reported a cumulative major molecular response $(MMR.AU)$ rate of 47% by 24 weeks, with a favorable safety and tolerability profile across all dose levels. Enliven plans to initiate a Phase 3 pivotal trial in 2026, aiming to position ELVN-001 as a competitive treatment option in the CML landscape. Enliven will discuss these findings during a webcast and conference call on June 13, 2025, at 1:30 p.m. ET.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.